Brimonidine (As Tartrate)
- Brimonidine (As Tartrate)
- No Brand Name
- Ophthalmic, Otic and Nasal Droplet
- 0.2%
- Bottle
- 5 mL
Each 100 mL Contains:
Brimonidine (As Tartrate) 0.2 g
Brimonidine (As Tartrate) 0.2 g
• Elevated Intraocular Pressure
Mechanism of Action
Alpha-2 adrenergic receptor agonist, decreases aqueous humor secretion, increases uveoscleral outflow
Pharmacokinetics
Onset of action: 2hr
Excretion: urine (74%)
Contraindications
• Hypersensitivity to product or components
• Children <2 years
Adverse Reactions
Oral dryness, Conjunctival hyperemia, Allergic conjunctivitis, Eye pruritus, Rash, Photophobia, Headache, Fatigue, Dizziness, Dyspepsia, Blepharitis, Eye discharge
Major Drug Interactions
Isocarboxazid – Linezolid – Phenelzine – Procarbazine – Rasagiline – Selegiline – Thalidomide - Ranylcypromine
Warnings
-
Recommendations for Patient
• Remove contact lenses before instilling eye drops, wait 15 min before reinserting contact lenses
• If >1 ophthalmic product is being administered, wait 5 minutes between instilling eye drops
Pregnancy Considerations
Category: B
Breastfeeding Considerations
It is not known whether this drug is excreted in milk.
To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Alpha-2 adrenergic receptor agonist, decreases aqueous humor secretion, increases uveoscleral outflow
Pharmacokinetics
Onset of action: 2hr
Excretion: urine (74%)
Contraindications
• Hypersensitivity to product or components
• Children <2 years
Adverse Reactions
Oral dryness, Conjunctival hyperemia, Allergic conjunctivitis, Eye pruritus, Rash, Photophobia, Headache, Fatigue, Dizziness, Dyspepsia, Blepharitis, Eye discharge
Major Drug Interactions
Isocarboxazid – Linezolid – Phenelzine – Procarbazine – Rasagiline – Selegiline – Thalidomide - Ranylcypromine
Warnings
-
Recommendations for Patient
• Remove contact lenses before instilling eye drops, wait 15 min before reinserting contact lenses
• If >1 ophthalmic product is being administered, wait 5 minutes between instilling eye drops
Pregnancy Considerations
Category: B
Breastfeeding Considerations
It is not known whether this drug is excreted in milk.
To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people